Pfizer Inc. PFE on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast ...

PHILADELPHIA -- Pfizer and BioNTech said Tuesday they have submitted Covid-19 vaccine data on children ages 5 to 11 to the US Food and Drug Administration for initial review, but are not yet seeking ...

March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement upon Ibrance and other, similar breast cancer medicines from Eli Lilly and ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

Pfizer highlighted the performance of a weight-loss drug it acquired in last year's deal to buy Metsera. Pfizer's stock closed 3% lower on Tuesday after investors were disappointed by limited midstage ...

China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more ...